Literature DB >> 33566263

Heterogeneity of radiation response in mesenchymal subtype glioblastoma: molecular profiling and reactive oxygen species generation.

Christopher P Cifarelli1,2, Angelica Jacques3, Andrey Bobko4.   

Abstract

BACKGROUND: Radiotherapy-induced tumor death remains critical in the successful first-line management of glioblastoma, whereas resistance to radiation serves as a major factor in disease progression. Mesenchymal shift has been identified as a driver in GBM recurrence, with gene expression associated with enhanced repair of macromolecular damage caused by radiation.
METHODS: Using distinct mesenchymal subtype GBM cells lines, radiation response was assessed by clonogenic assay and orthotopic mouse tumor model. RNA-sequencing was performed in the setting of increasing radiation dosing while real-time assessment of ROS generation was achieved by the measurement of hydroxyl spin trap adducts via electron paramagnetic resonance.
RESULTS: Radiation-induced cell death determined by clonogenic assay was significantly different at low dose (4-8 Gy) between the resistant U3035 cells and the sensitive U3020 cells. Similar trends were present in the in vivo NSG mouse model following radiation dosing on post-implantation day 7-10, with the rate of reduction in tumor bioluminescence reversing between the U3020 and U3035 cells after the third dose of radiation. Changes in gene expression following radiation determined by RNA-sequencing indicate both U3035 and U3020 cells demonstrate a shift toward more mesenchymal profiles, with concurrent shift away from pro-neural subtype gene expression in the U3020 cells that appeared to develop resistance to radiation in vivo. Persistence of ROS generated following radiation was greater in U3020 cells shown to be more sensitive to radiation.
CONCLUSIONS: Despite the same molecular classification, distinct GBM cell lines can demonstrate differential response to radiation and potential for mesenchymal shift associated with radiation resistance.

Entities:  

Keywords:  Glioblastoma; Mesenchymal shift; PCA; Radiation; Reactive oxygen species

Mesh:

Substances:

Year:  2021        PMID: 33566263      PMCID: PMC8005479          DOI: 10.1007/s11060-021-03707-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  30 in total

1.  ESTRO-ACROP guideline "target delineation of glioblastomas".

Authors:  Maximilian Niyazi; Michael Brada; Anthony J Chalmers; Stephanie E Combs; Sara C Erridge; Alba Fiorentino; Anca L Grosu; Frank J Lagerwaard; Giuseppe Minniti; René-Olivier Mirimanoff; Umberto Ricardi; Susan C Short; Damien C Weber; Claus Belka
Journal:  Radiother Oncol       Date:  2016-01-06       Impact factor: 6.280

2.  Intraoperative radiotherapy for glioblastoma: an international pooled analysis.

Authors:  Gustavo R Sarria; Elena Sperk; Xiaodi Han; Gustavo J Sarria; Frederik Wenz; Stefanie Brehmer; Bing Fu; Siming Min; Hongjun Zhang; Shusen Qin; Xiaoguang Qiu; Daniel Hänggi; Yasser Abo-Madyan; David Martinez; Carla Cabrera; Frank A Giordano
Journal:  Radiother Oncol       Date:  2019-10-16       Impact factor: 6.280

3.  Phase I/II study of resection and intraoperative cesium-131 radioisotope brachytherapy in patients with newly diagnosed brain metastases.

Authors:  A Gabriella Wernicke; Menachem Z Yondorf; Luke Peng; Samuel Trichter; Lucy Nedialkova; Albert Sabbas; Fridon Kulidzhanov; Bhupesh Parashar; Dattatreyudu Nori; K S Clifford Chao; Paul Christos; Ilhami Kovanlikaya; Susan Pannullo; John A Boockvar; Philip E Stieg; Theodore H Schwartz
Journal:  J Neurosurg       Date:  2014-05-02       Impact factor: 5.115

4.  Perilesional Resection of Glioblastoma Is Independently Associated With Improved Outcomes.

Authors:  Wajd N Al-Holou; Tiffany R Hodges; Richard G Everson; Jacob Freeman; Shouhao Zhou; Dima Suki; Ganesh Rao; Sherise D Ferguson; Amy B Heimberger; Ian E McCutcheon; Sujit S Prabhu; Frederick F Lang; Jeffrey S Weinberg; David M Wildrick; Raymond Sawaya
Journal:  Neurosurgery       Date:  2020-01-01       Impact factor: 4.654

Review 5.  GammaTile®: Surgically targeted radiation therapy for glioblastomas.

Authors:  Dominic J Gessler; Clara Ferreira; Kathryn Dusenbery; Clark C Chen
Journal:  Future Oncol       Date:  2020-07-03       Impact factor: 3.404

6.  Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.

Authors:  Cassie N Kline; Nancy M Joseph; James P Grenert; Jessica van Ziffle; Eric Talevich; Courtney Onodera; Mariam Aboian; Soonmee Cha; David R Raleigh; Steve Braunstein; Joseph Torkildson; David Samuel; Michelle Bloomer; Alejandra G de Alba Campomanes; Anuradha Banerjee; Nicholas Butowski; Corey Raffel; Tarik Tihan; Andrew W Bollen; Joanna J Phillips; W Michael Korn; Iwei Yeh; Boris C Bastian; Nalin Gupta; Sabine Mueller; Arie Perry; Theodore Nicolaides; David A Solomon
Journal:  Neuro Oncol       Date:  2017-05-01       Impact factor: 12.300

7.  Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma.

Authors:  Matthew Z Sun; Taemin Oh; Michael E Ivan; Aaron J Clark; Michael Safaee; Eli T Sayegh; Gurvinder Kaur; Andrew T Parsa; Orin Bloch
Journal:  J Neurosurg       Date:  2015-03-13       Impact factor: 5.115

8.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Authors:  Roger Stupp; Sophie Taillibert; Andrew Kanner; William Read; David Steinberg; Benoit Lhermitte; Steven Toms; Ahmed Idbaih; Manmeet S. Ahluwalia; Karen Fink; Francesco Di Meco; Frank Lieberman; Jay-Jiguang Zhu; Giuseppe Stragliotto; David Tran; Steven Brem; Andreas Hottinger; Eilon D. Kirson; Gitit Lavy-Shahaf; Uri Weinberg; Chae-Yong Kim; Sun-Ha Paek; Garth Nicholas; Jordi Bruna; Hal Hirte; Michael Weller; Yoram Palti; Monika E. Hegi; Zvi Ram
Journal:  JAMA       Date:  2017-12-19       Impact factor: 56.272

9.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

Authors:  Timothy F Cloughesy; Aaron Y Mochizuki; Joey R Orpilla; Willy Hugo; Alexander H Lee; Tom B Davidson; Anthony C Wang; Benjamin M Ellingson; Julie A Rytlewski; Catherine M Sanders; Eric S Kawaguchi; Lin Du; Gang Li; William H Yong; Sarah C Gaffey; Adam L Cohen; Ingo K Mellinghoff; Eudocia Q Lee; David A Reardon; Barbara J O'Brien; Nicholas A Butowski; Phioanh L Nghiemphu; Jennifer L Clarke; Isabel C Arrillaga-Romany; Howard Colman; Thomas J Kaley; John F de Groot; Linda M Liau; Patrick Y Wen; Robert M Prins
Journal:  Nat Med       Date:  2019-02-11       Impact factor: 53.440

10.  Radiosensitivity in breast cancer assessed by the histone γ-H2AX and 53BP1 foci.

Authors:  Cholpon S Djuzenova; Ines Elsner; Astrid Katzer; Eike Worschech; Luitpold V Distel; Michael Flentje; Bülent Polat
Journal:  Radiat Oncol       Date:  2013-04-24       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.